The conference will have talks by leading scientists and doctors from around the world and feature new research papers on the uses of GcMAF to restore the body’s immune system to full strength to fight diseases, autism and cancer.
St Peter Port, Guernsey (February 26, 2013) — The world’s first GcMAF conference will be held on the 19th, 20th and 21st of April in the attractive woodland Conference Centre at the Holiday Inn Frankfurt, Germany. Sponsored by Immuno Biotech Ltd, the conference will have talks by leading scientists and doctors from around the world and feature new research papers on the uses of GcMAF to restore the body’s immune system to full strength to fight diseases, autism and cancer.
David Noakes, Immuno Biotech’s CEO, said, “When research scientists and doctors meet to add together their individual results into one whole, the science takes a great step forward. It’s a pooling of the latest discoveries. We expect to come up with a definitive list of synergistic treatments which will allow doctors to treat stage 3 and some stage 4 cancers with the same 80% success that they achieve with GcMAF alone on stage 2 cancers.
“At the moment GcMAF eradicates autism in 15% of cases. By identifying the best complimentary treatments we hope to take that up to 40%. Amongst others, we hope to take ME/CFS from 30 to 50% success. The workshops will encourage informal networking and new ideas. We have a packed programme of talks by leading GcMAF researchers, doctors reporting on their success at eradicating cancer, autism and ME/CFS with GcMAF and, as a result, registrations are already flooding in.”
Registration is open now for doctors and research scientists at http://gcmafconference.org and, from March 20th, registration opens for members of the public and patients wishing to learn more about GcMAF.
Immuno Biotech extracts and isolates GcMAF molecules from healthy human blood. As part of the process of tests and assays to ensure its GcMAF is active, it has been conducting laboratory research into the methods by which GcMAF destroys cancers cells, and is publishing its first three research papers at international conferences on cancer, immunology and autism. Currently there are over 60 research papers on GcMAF by 142 eminent scientists with new peer-reviewed papers being added at an increasing rate from university teams and doctors from dozens of countries.
The quality of Immuno Biotech’s GcMAF has made it the World’s leading supplier and the provider of choice for doctors and scientists with the company being cited in eleven research papers to date. Many of the independent research papers on GcMAF are listed on its website http://www.gcmaf.eu.
Background
GcMAF is a vital part of the human immune system, which doesn’t work without it. However, many diseases including cancer attempt to prevent production of the body’s own GcMAF and, if successful, that prevents the immune system from fighting them, resulting in the diseases growing unchecked and becoming chronic.
Immuno Biotech extracts GcMAF molecules from healthy blood. A weekly injection of a tiny clear drop restores the level of GcMAF in the blood to normal, effectively one millionth of a blood transfusion. That enables the body’s own immune system to fight the disease, with the only occasional side effects being mild, cold-like symptoms as the immune system starts to function normally. The time it takes for the body to fight the infection and return to being able to produce normal levels of its own GcMAF depends on the severity of the infection or cancer. An eight week course costs €660 including shipping so a typical 24 week course costs under €2000 – a fraction of the cost of conventional treatments. Immuno Biotech has supplied 4,000 patients through 300 doctors in 30 nations.
Immuno Biotech Contact: Beate Keisa, Immuno Biotech Ltd., Ph: 0044 7781 411737, Website: http://www.gcmaf.eu and click “contact” at the top to email.
